Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation
When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF
From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5)
H2FPEF Score for Predicting Future Heart Failure in Stable Outpatients With Cardiovascular Risk Factors
SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL
Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes